s20098 has been researched along with Recrudescence in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baus, C; Dogui, R; Kennel, J; Riemenschneider, M; Siebert, S | 1 |
| Noori, HR; Spanagel, R; Vengeliene, V | 1 |
| Aalto-Setälä, M; Brignone, M; Campbell, R; Cure, S; Danchenko, N; Diamand, F; Hallinen, T; Kolasa, K; Koponen, H; Soini, E | 1 |
| Goodwin, GM | 2 |
| Gorwood, P; Le Strat, Y | 1 |
| Lam, RW | 1 |
| Kennedy, SH | 2 |
| Llorca, PM | 1 |
| Demyttenaere, K | 1 |
| Smirnova, VN; Tiuvina, NA | 1 |
| Emsley, R; Kennedy, SH | 1 |
7 review(s) available for s20098 and Recrudescence
| Article | Year |
|---|---|
Agomelatine, an innovative pharmacological response to unmet needs.
Topics: Acetamides; Animals; Antidepressive Agents; Chronic Disease; Circadian Rhythm; Depressive Disorder, Major; Humans; Models, Animal; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome | 2008 |
Innovation translates into antidepressant effectiveness.
Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Severity of Illness Index; Time Factors; Treatment Outcome | 2008 |
Addressing circadian rhythm disturbances in depressed patients.
Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Sleep; Sleep Disorders, Circadian Rhythm; Time Factors; Treatment Outcome | 2008 |
Treating each and every depressed patient.
Topics: Acetamides; Age Factors; Antidepressive Agents; Anxiety; Chronic Disease; Circadian Rhythm; Depressive Disorder, Major; Female; Humans; Male; Patient Selection; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Severity of Illness Index; Sex Factors; Sleep; Time Factors; Treatment Outcome | 2008 |
Agomelatine: efficacy at each phase of antidepressant treatment.
Topics: Acetamides; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Psychiatric Status Rating Scales; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Sleep Wake Disorders | 2009 |
The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission.
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Humans; Medication Adherence; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Remission Induction | 2010 |
Agomelatine: a narrative review.
Topics: Acetamides; Antidepressive Agents; Antidepressive Agents, Second-Generation; Comparative Effectiveness Research; Depressive Disorder, Major; Humans; Placebos; Randomized Controlled Trials as Topic; Recurrence | 2011 |
1 trial(s) available for s20098 and Recrudescence
| Article | Year |
|---|---|
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.
Topics: Acetamides; Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Psychiatric Status Rating Scales; Recurrence; Treatment Outcome | 2006 |
6 other study(ies) available for s20098 and Recrudescence
| Article | Year |
|---|---|
Agomelatine-Related Shift to Mania in a Patient With Recurrent Depressive Disorder.
Topics: Acetamides; Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Female; Humans; Recurrence | 2017 |
Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.
Topics: Acetamides; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Aminopyridines; Animals; Choice Behavior; Circadian Rhythm; Disease Models, Animal; Indoles; Male; Melatonin; Motor Activity; Rats, Wistar; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists | 2015 |
Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland.
Topics: Acetamides; Antidepressive Agents; Bupropion; Cost-Benefit Analysis; Decision Trees; Depressive Disorder, Major; Finland; Humans; Markov Chains; Models, Theoretical; Piperazines; Recurrence; Sertraline; Sulfides; Treatment Outcome; Venlafaxine Hydrochloride; Vortioxetine | 2017 |
Major depression is sometimes described as the common cold of psychiatry.
Topics: Acetamides; Animals; Antidepressive Agents; Chronic Disease; Circadian Rhythm; Depressive Disorder, Major; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome | 2008 |
Agomelatine: new drug. Adverse effects and no proven efficacy.
Topics: Acetamides; Animals; Antidepressive Agents; Bias; Carcinogens; Clinical Trials as Topic; Cyclohexanols; Depression; Depressive Disorder; Double-Blind Method; Drug Approval; Europe; Fluoxetine; Humans; Hypnotics and Sedatives; Melatonin; Paroxetine; Psychiatric Status Rating Scales; Receptors, Melatonin; Recurrence; Selective Serotonin Reuptake Inhibitors; Suicide; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
[A comparative evaluation of the efficacy of valdoxan (agomelatine) in recurrent depression and bipolar affective disorder].
Topics: Acetamides; Adult; Antidepressive Agents; Bipolar Disorder; Circadian Rhythm; Depressive Disorder; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Psychometrics; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2012 |